# Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

> **NCT02419638** · — · WITHDRAWN · sponsor: **Brigham and Women's Hospital**

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Rebif (IFN β-1a subcutaneous three times per week)
- **DRUG:** Tecifdera (dimethyl fumarate)

## Key facts

- **NCT ID:** NCT02419638
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-05
- **Primary completion:** 2015-12
- **Final completion:** 2016-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Collaborative decision between study PI and sponsor.
- **Last updated:** 2016-02-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02419638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02419638, "Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02419638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*